{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:29:47Z","timestamp":1789273787005,"version":"build-2803163510"},"reference-count":64,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Recently, 3 oral Janus kinase (JAK) inhibitors\u2014abrocitinib, baricitinib, and upadacitinib\u2014were approved in many regions around the world for the treatment of moderate\u2013severe atopic dermatitis (AD). These JAK inhibitors generally have rapid onset of action and short half-life. Higher doses of abrocitinib and upadactinib even demonstrated superior efficacy to dupilumab. However, JAK inhibitors can be associated with rare serious and potentially life-threatening adverse events. Heterogeneity in study designs and lack of head-to-head studies make safety comparison between JAK inhibitors difficult. Dose reduction and patient selection are the most important considerations for risk mitigation. This narrative review examines the efficacy data for abrocitinib, baricitinib, and upadacitinib from large phase III double-blinded randomized controlled trials in AD and discusses risk stratification for oral JAK inhibitors in AD patients.\n                  <\/jats:p>","DOI":"10.1089\/derm.2023.0058","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T13:13:25Z","timestamp":1690895605000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1177","volume":"35","author":[{"given":"Shanthi","family":"Narla","sequence":"first","affiliation":[{"name":"From the,  Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.022"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1512404"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010037"},{"issue":"3","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2022.11869","article-title":"First systemic treatment for severe alopecia is approved","volume":"328","author":"Rubin R.","year":"2022","unstructured":"Rubin R. First systemic treatment for severe alopecia is approved. JAMA, 2022; 328(3):235\u2013235.","journal-title":"JAMA"},{"key":"e_1_3_1_8_2","unstructured":"RINVOQ\u00ae (Upadacitinib) Receives Its Sixth U.S. FDA Approval [press release]. 2022. Available at: https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-receives-its-sixth-us-fda-approval.htm. Accessed April10 2023."},{"key":"e_1_3_1_9_2","unstructured":"Brunk D . FDA approves two JAK-1 inhibitors for moderate to severe atopic dermatitis. 2022. Available at: https:\/\/www.mdedge.com\/dermatology\/article\/250777\/atopic-dermatitis. Accessed Feb26 2023."},{"key":"e_1_3_1_10_2","unstructured":"Updates on OLUMIANT\u00ae (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis [press release]. 2022. Available at: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda. Accessed April10 2023."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/23312025.2015.1103459"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010030"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.002"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3519"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"e_1_3_1_20_2","first-page":"39","article-title":"Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency","volume":"178","author":"Notarangelo LD","year":"2000","unstructured":"Notarangelo LD, , Giliani S, , Mazza C, et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev, 2000; 178:39\u201348.","journal-title":"Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.347"},{"key":"e_1_3_1_24_2","unstructured":"New TYK2 inhibitors: a growing race to top Bristol Myers [press release]. 2022. Available at: https:\/\/www.biopharmadive.com\/news\/tyk2-inhibitors-jak-protein-startups-biotech\/633635\/. Accessed April10 2023."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1273"},{"key":"e_1_3_1_28_2","unstructured":"Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine [press release]. 2020. Available at: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-and-incyte-announce-top-line-results-phase-3-study-breeze. Accessed April10 2023."},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21630"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.028"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17278"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"e_1_3_1_33_2","unstructured":"ClinicalTrials.gov. A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS). 2019. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03952559. Accessed July17 2021."},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_3_1_38_2","unstructured":"RINVOQ\u2122 (upadacitinib) Achieved Superiority Versus DUPIXENT\u00ae (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis [press release]. 2020. Available at: https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-adults-with-atopic-dermatitis.htm. Accessed April10 2023."},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S306378"},{"key":"e_1_3_1_43_2","first-page":"S115","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena-Woods C.","year":"2017","unstructured":"Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care, 2017; 23(8 Suppl):S115\u2013s123.","journal-title":"Am J Manag Care"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218282"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-016-1090-x"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.573542"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000795"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000520"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16482"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11232"},{"key":"e_1_3_1_51_2","volume-title":"EMA Confirms Xeljanz to Be Used with Caution in Patients at High Risk of Blood Clots","author":"European Medicine Agency","year":"2019","unstructured":"European Medicine Agency. EMA Confirms Xeljanz to Be Used with Caution in Patients at High Risk of Blood Clots. Amsterdam, Netherlands: European Medicine Agency; 2019."},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205847"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2823"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"},{"issue":"6","key":"e_1_3_1_58_2","first-page":"278","article-title":"Janus kinase signaling in inflammatory bowel disease","volume":"17","author":"Cohen BL.","year":"2021","unstructured":"Cohen BL. Janus kinase signaling in inflammatory bowel disease. Gastroenterol Hepatol, 2021; 17(6):278\u2013281.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.29004.sna"},{"issue":"1","key":"e_1_3_1_61_2","first-page":"i43","article-title":"JAK-inhibitors","volume":"58","author":"Fragoulis GE","year":"2019","unstructured":"Fragoulis GE, , McInnes IB, , Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford), 2019; 58(Suppl 1):i43\u2013i54.","journal-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford)"},{"key":"e_1_3_1_62_2","unstructured":"FDA. Highlights of prescribing information Xeljanz. 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. Accessed April10 2023."},{"key":"e_1_3_1_63_2","unstructured":"Highlights of Prescribing Information; Rinvoq\u00ae (upadacitinib) Extended-Release Tablets for Oral Use Initial U.S. Approval: 2019. U.S. FDA; 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s003lbl.pdf. Accessed April10 2023."},{"key":"e_1_3_1_64_2","unstructured":"FDA US. Highlights of Prescribing Information; Olumiant (baricitinib) tablets for oral use. 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf. Accessed April10 2023."},{"key":"e_1_3_1_65_2","unstructured":"FDA. Highlights of Prescribing Information Cibinqo. 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf. Accessed April10 2023."}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2023.0058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:08:28Z","timestamp":1777399708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2023.0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":64,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["10.1089\/derm.2023.0058"],"URL":"https:\/\/doi.org\/10.1089\/derm.2023.0058","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}